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Purpose — We wanted to examine the potential of the Scandina-
vian Sarcoma Group (SSG) Central Register, and evaluate refer-
ral and treatment practice for soft-tissue sarcomas in the extremi-
ties and trunk wall (STS) in the Nordic countries.
Background — Based on incidence rates from the literature, 
8,150 (7,000–9,300) cases of STS of the extremity and trunk wall 
should have been diagnosed in Norway, Finland, Iceland, and 
Sweden from 1987 through 2011. The SSG Register has 6,027 
cases registered from this period,  with 5,837 having complete 
registration of key variables. 10 centers have been reporting to 
the Register. The 5 centers that consistently report treat approxi-
mately 90% of the cases in their respective regions. The remaining 
centers have reported all the patients who were treated during 
certain time periods, but not for the entire 25-year period.
Results — 59% of patients were referred to a sarcoma center 
untouched, i.e. before any attempt at open biopsy. There was an 
improvement from 52% during the fi rst 5 years to 70% during 
the last 5 years. 50% had wide or better margins at surgery. Wide 
margins are now achieved less often than 20 years ago, in paral-
lel with an increase in the use of radiotherapy. For the centers 
that consistently report, 97% of surviving patients are followed 
for more than 4 years. Metastasis-free survival (MFS) increased 
from 67% to 73% during the 25-year period.
Interpretation — The Register is considered to be representa-
tive of extremity and trunk wall sarcoma disease in the popula-
tion of Scandinavia, treated at the reporting centers. There were 
no clinically signifi cant differences in treatment results at these 
centers.
■
The Scandinavian Sarcoma Group (SSG) Central Regis-
ter was started in 1986. The aim was to make it population-
based, like the Southern Sweden Sarcoma Register (Gustafson 
1994). The purpose of this report is to summarize the status of 
extremity/trunk wall soft-tissue sarcoma (STS) diagnosis and 
treatment in the participating countries.
The Nordic population of approximately 27 million people 
can be identifi ed based on personal identifi cation numbers. 
There has been less internal migration than in North America, 
the health system is public, and there is a tradition of collabo-
ration and data sharing between treatment centers. 
True incidence fi gures of extremity and trunk wall STS are 
diffi cult to calculate, as national cancer registries have differ-
ent defi nitions of which entities constitute an STS and different 
defi nitions of tumor sites and locations. The reported propor-
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tion of retroperitoneal/organ-localized STS  also varies widely, 
from 15% (Fletcher et al. 2013) to 50% (Toro et al. 2006). 
Consequently, incidence rates for orthopedic STS vary 
between 1.4 per 100,000 (Weiss and Goldblum 2001) and 4 
per 100,000 in the European Society for Medical Oncology 
(ESMO) guidelines (Casali et al. 2009) and 4.7 per 100,000  in 
the World Health Organisation (WHO) classifi cation (Fletcher 
et al. 2013). The Cancer Registry of Norway has suggested 
a fi gure of 5.0 per 100,000 for all soft-tissue sarcoma. In the 
RARECARE project, 76 national cancer registries (45,000 
patients) were used to calculate median crude incidence rates 
for the period 1988 through 2002 (Stiller et al. 2013). The rate 
for soft-tissue sarcoma at all sites was 4.7 per 100,000, and it 
was 1.5 per 100,000 for extremity/trunk wall-localized tumors. 
2 Scandinavian, truly population-based regional registers—in 
Aarhus (Maretty-Nielsen et al. 2013) and Lund (Gustafson 
1994)—have done incidence calculations. It is notable that 
these 2 registers have exactly the same incidence fi gures for 
extremity/trunk wall STS: 1.8 per 100,000. In these reports, 
all cases in the regions were actively tracked down—combin-
ing hospital registers, national cancer registries, and pathology 
registries—and quality-evaluated using review pathology for 
inconsistent cases.
Based on the mean populations of Norway, Finland, Ice-
land, and Sweden during the period 1987–2011 (19 million) 
(Haagensen 2012) and an annual incidence of STS in the 
extremities and trunk wall of 1.5–2.0 per 100,000, approxi-
mately 8,150 (7,000–9,300) STSs would have occurred in 
these countries in that period. The Register actually had 6,027 
patients, 5,837 of whom had complete registration. 
10 sarcoma centers have been reporting to the Register 
(Table 1). From Norway and Sweden, 4 tumor centers (in 
Stockholm, Oslo, Lund, and Bergen), representing approxi-
mately 70% of the Scandinavian population, have been report-
ing all their cases consistently during the entire period. They 
treat > 90% of patients in their catchment area. 2 centers in 
Finland, treating approximately 50% of all Finnish sarcomas, 
on. Treatment variables were detailed for the surgical proce-
dure, but not for chemotherapy or radiation parameters. It was 
merely recorded whether or not chemotherapy or radiotherapy 
was given. Since 2005, more details of radiotherapy fraction-
ation and dose have been added. The 2014 registration and 
follow-up forms are available from the SSG website at http://
www.ssg-org.net. 
A number of key variables have to be completed to qualify 
for inclusion in the Register-derived studies (Table 2). 
Guidelines for interpretation and variable defi nitions are 
also available at the SSG website. At the 2009 revision, 10 
mm of healthy tissue or intact fascia was established as the 
cutoff between marginal and wide margins. Previously, a 
wide margin was just defi ned as a “cuff of healthy tissue” or 
intact fascia in accordance with Enneking’s margin defi nitions 
(Enneking et al. 1980). 
The SSG recommends that patients should be followed 
for at least 5 years from diagnosis or last relapse. However, 
10-year follow-up should be considered for patients aged less 
Table 1. Total numbers (percentages) of patients registered in 5 time periods since the start of 
the Scandinavian Sarcoma Group Central Register, which includes population data from Norway, 
Finland, and Sweden
 
Sarcoma 1987–1991 1992–1996 1997–2001 2002–2006 2007–2011 Total
center n = 1,045 n = 1,077 n = 1,190 n = 1,287 n = 1,238 n = 5,837
Oslo 214 (21) 228 (21) 268 (23) 324 (25) 367 (30) 1,373 (24)
Stockholm 205 (20) 237 (22) 274 (23) 299 (23) 235 (19) 1,250 (22)
Lund 164 (16) 155 (14) 145 (12) 164 (13) 162 (13) 790 (14)
Gothenburg 139 (13) 137 (13) 120 (10) 128 (10) 134 (11) 658 (11)
Helsinki 109 (10) 133 (12) 129 (11) 120 (9) 67 (5) 558 (10)
Bergen 74 (7) 65 (6) 74 (6) 87 (7) 94 (8) 394 (7)
Umeå 37 (4) 38 (4) 79 (7) 73 (6) 94 (8) 321 (6)
Linköping 55 (5) 19 (2) 9 (1) 36 (3) 14 (1) 133 (2)
Tampere 11 (1) 20 (2) 6 (1) 21 (2) 66 (5) 124 (2)
Trondheim 28 (3) 40 (4) 39 (3) 15 (1) 0 (0) 122 (2)
Other hospitals 9 5 47 (4) 20 (1) 5 86 (1)
have been reporting, and the  larg-
est center (in Helsinki) has com-
plete reports. The remaining centers 
have mostly reported all the patients 
treated during certain time periods 
but have not reported them at all 
during other periods. 
The Register and defi nitions 
Designated physicians at each 
center are responsible for data col-
lection for the SSG Central Regis-
ter. From the start, referral practice, 
diagnostic procedures, pathology 
diagnoses, and surgical staging 
(size, depth, site, location, and com-
partmentalization) were focused 
Table 2. Variables that must be recorded to qualify for inclusion in 
the Scandinavian Sarcoma Group Central Register for extremity 
and trunk wall sarcoma
• Sarcoma center responsible for treatment and follow-up reporting
• Age at diagnosis
• Sex
• Date of diagnosis
• Referral pattern (after: virgin, needle biopsy, open biopsy/  
intralesional excision, marginal excision, wide excision, local recur-
rence, metastasis)
• Metastases at diagnosis
• Tumor location, size and depth
• Histology
• Malignancy grade/malignancy grade not applicable
• Number of operations for primary tumor
• Type of operation (local excision or amputation)
• Surgical margin
• Adjuvant treatment or protocol number
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than 70 years. Follow-up includes physical examination and 
chest radiography (conventional or computed tomography 
(CT)), and magnetic resonance imaging (MRI) of the primary 
tumor site when deemed necessary. 
To safeguard against systematic bias when “choosing” 
patients for reporting, centers were tested for adequate follow-
up reporting in 2 time periods: 1987–1989 and 2000–2006. 
More than 75% of patients followed for > 4 years were consid-
ered necessary to pass this test. 5 continuously reporting cen-
ters (Stockholm, Lund, Helsinki, Oslo, and Bergen) passed the 
test and were included for outcome analysis of all their cases. 
3 centers reported adequate follow-up for > 75% of patients 
during a certain time period, and were included with patients 
diagnosed before 2000 (Umeå, Linköping, and Trondheim). 2 
centers did not pass the test and were excluded for outcome 
reporting (Gothenburg and Tampere). However, they have 
reported primary data for most of their patients, and these are 
included for statistics of the demographic variables. 
After this test was passed, 4,090 patients remained for out-
come analysis of local recurrence (LR) rates and metastasis-
free survival (MFS).
At the 8 centers, including patients treated before 2000, 
97% of patients had been followed for more than 4 years. Of 
the patients treated during 2000–2006 by one of the 5 continu-
ously reporting centers, 87% had been followed for more than 
4 years in 2013.
Pathology 
Classifi cation of sarcomas is based on the WHO classifi cation 
system for soft-tissue sarcomas (Fletcher et al. 2013) (Table 
3). As an example of changing terminology, the diagnosis 
malignant fi brous histiocytoma/undifferentiated pleomorphic 
sarcoma became reduced from 40% in the period 1987–1996 
to 24% in 2007–2011. Of the 5,837 STS cases, 1,463 (25%) 
have been peer reviewed by the SSG morphology group. In 
1987–1996, 44% of preoperative morphological diagnoses 
were based on cytology only. In 2007–2011, true-cut biopsies 
were more often added and only 22% of preoperative diagno-
ses relied exclusively on cytology. The use of open biopsies 
became reduced from 24% to 4.4% during the 25-year period. 
This change—of using more true-cut biopsies—was caused 
by the need for ancillary histopathological analyses, includ-
ing genetic analyses. In the SSG, the grading of sarcomas has 
been based on a 4-tier grading system, principally based on 
Brooders’ grading mode (Broders et al. 1939) (Bjerkehagen 
et al. 2009). The French Federation Nationale des Centres de 
Lutte Contre le Cancer (FNCLCC) system for grading of soft-
tissue sarcoma (Coindre 2006)  is now more widely used. It 
is recommended by the WHO (Fletcher et al. 2013), and has 
been recorded in the SSG Register since 2006. The gradual 
introduction of a new grading system has not resulted in any 
change in the rate of sarcomas that are graded as high-grade 
malignant, which has been about three-quarters of the total 
throughout the period (Table 4.) 
Radiology
For diagnostic tumor imaging, there has been a clear shift 
during the period 1987–2011 from CT to MRI. A simple pro-
tocol based on a study from 1985 (Weekes et al. 1985) is still 
recommended. The tumor size reported to the SSG Central 
Register was based on the histopathological specimen during 
the early years, but it is now increasingly based on preopera-
tive MRI. 
Statistics
Pearson’s exact chi-squared test was used for comparisons of 
categorical variables between groups. Metastasis-free survival 
(MFS) and local recurrence (LR) rates following treatment in 
a certain time period were estimated using the Kaplan-Meier 
method, and the log-rank test was used for comparing groups. 
For MFS, follow-up was terminated if a patient had a metas-
tasis or died from the disease, which were both considered 
events. The rest of the patients were censored at their latest 
Table 3. Distribution of histological subtypes of sarcomas in different 
time periods in the Scandinavian Sarcoma Group Central Register
 
Histological subtype  1987–1996  1997–2006  2007–2011  Total (%)   
 n = 2,122 n = 2,477 n = 1,238 n = 5,837
Liposarcoma 13% 19% 22% 1,019 (18)
Solitary fi brous tumor 2% 1% 1% 70 (1)
Myxofi brosarcoma 0% 4% 11% 241 (4)
Fibrosarcoma 3% 4% 1% 193 (3)
Leiomyosarcoma 9% 13% 15% 699 (12)
Rhabdomyosarcoma 2% 1% 1% 80 (1)
Angiosarcoma 1% 1% 2% 85 (2)
Malignant peripheral 
   nerve sheath tumor 5% 5% 4% 269 (4)
Synovial sarcoma 8% 6% 6% 392 (7)
Ewing sarcoma 2% 1% 2% 99 (2)
Other sarcoma 7% 8% 8% 454 (8)
Malignant fi brous 
   histiocytoma a 40% 31% 24% 1,921(33)
Unclassifi ed sarcoma 5% 6% 3% 312 (5)
a (undifferentiated pleomorphic sarcoma)  
Table 4. Distribution of malignancy grades among 5,462 soft tissue 
sarcomas according to Broders respectively 210 according to 
FNCLCC a in different time periods. Rare sarcomas, traditionally not 
graded are excluded
Broders 1987–1996 1997–2006 2007–2011 Total
 I   8% 12% 15% 606
 II 14% 14% 14% 759
 III 34% 26% 21% 1,539
 IV 44% 48% 50% 2,558
FNCLCC a   > 2006 
 1   24% 50
 2   34% 72
 3   42% 88
a Fédération Nationale des Centres de Lutte Contre le Cancer. 
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follow-up date or at death from unrelated or unknown causes. 
For LR, follow-up was ended if a patient had a local recur-
rence, which was considered to be an uncensored event. The 
rest of the patients were censored at their latest follow-up date 
or at death. Results are reported using hazard ratios (HRs) 
with 95% confi dence interval (CI). 
The effects of potential prognostic factors on MFS and LR, 
at different centers were computed using Cox multiple regres-
sion analysis with the likelihood ratio test (Figure 3). These 
factors were analysed for 5 centers and each center were 
then compared to the center with closest to median survival 
results. Confi dence intervals are given in Figure 3. Differences 
are illustrated by plotting a standard patients survival curve 
at different centers. The prognostic factors were sex, age at 
diagnosis (1-year increments), tumor size (1-cm increments), 
tumor depth (deeper vs. subcutaneous location) and grade of 
malignancy (high-grade vs. low-grade). Log-minus-log sur-
vival plots were used to confi rm proportionality. These factors 
are shown to be of univariate prognostic value in many studies 
(Trovik et al. 2001). The most common values for the categor-
ical covariates and the mean values for continuous covariates 
were chosen for the plots. 
Any p-value of ≤ 0.05 was considered statistically signifi -
cant. Data management and all the statistical analyses were 
performed on anonymized data using PASW Statistics (18.0–
23.0) and Medlog.
59% of the patients were referred to a sarcoma center 
untouched, before any attempt at open biopsy. There was an 
improvement from 52% during the fi rst 5-year period to 70% 
during the last 5-year period (Table 5). This improvement 
led to a reduction in the proportion of patients who needed 
more than 1 operation to obtain adequate margins after pri-
mary tumor resection. During the period 1987–1997, 29% of 
patients needed more than 1 operation. During 2007–2011, 
that proportion was 19%. 
79% of those tumors operated outside a sarcoma center 
were  < 5 cm in diameter, and 62% were subcutaneous. SSG 
guidelines permit removal of small, subcutaneous lipoma-like 
tumors outside sarcoma centers.
25% of patients still undergo surgery without any preopera-
tive histopathologic examination, including patients operated 
primarily outside  sarcoma centers and those who are operated 
at a center, based on radiology alone.  
The proportion of patients with metastasis identifi ed during 
diagnosis or in the fi rst month thereafter was 8% in 1987–
1996, 8% in 1997–2006, and 10% in 2007–2011. The median 
size of the tumor recorded at diagnosis, 7 (1–50) cm, did not 
change between these time periods.
More than 30% of tumors were subcutaneous, a further indi-
cation that the Register is representative of the STS popula-
tion. Signifi cantly more tumors are now registered with intra-
muscular location (p < 0.001) than 20 years ago (Table 6). 
Table 5. Percentage of cases and total number of cases referred to sarcoma center 
virgin (including fi ne-needle or coarse-needle biopsy) or after surgical procedures/
recurrence in 3 time periods, as reported in the Scandinavian Sarcoma Group Cen-
tral Register             
 1987–1996 1997–2006 2007–2011 Total
 n = 2,122 n = 2,477 n = 1,238 n = 5,837
Virgin/needle biopsy 52% 59% 70% 3,447
Open biopsy/ surgery 36% 34% 25% 1,930
Referred after local recurrence 8% 4% 2% 276
Referred after metastasis 4% 3% 3% 184
Ethics and funding
As a retrospective quality-assurance project, 
the study was approved by the Ombudsman 
for Privacy in Research, Norwegian Social Sci-
ence Data Services. The study was conducted 
in accordance with the Helsinki Declaration of 
1975, as revised in 2000. The SSG Central Reg-
ister was initially (in 1986) granted a general 
approval for research on sarcoma treatment in 
Scandinavia. With new standards for research 
ethics since 2005, patient consent for reporting 
data to the SSG Central Register has been intro-
duced.
The study was supported by the National 
Advisory Unit on sarcomas in Norway, and by 
the Swedish Cancer Society. The SSG Central 
Register is also supported by the National Advi-
sory Unit on sarcomas in Norway and by the 
Swedish Cancer Society.
Results
There was a slight male preponderance (at 53%) 
and median age at diagnosis was 62 (0–103) 
years. The distributions of these variables did 
not change in Scandinavia during the years of 
monitoring.
Table 6. Site and depth of tumors in soft-tissue sarcoma (STS) cases according 
to time period, as reported in the Scandinavian Sarcoma Group Central Register
 
 1987–1996 1997–2006 2007–2011 Total
 n = 2,122 n = 2,477 n = 1,238 n = 5,837
Site
 Trunk wall 15% 15% 15% 878
 Upper extremity 21% 20% 20% 1,186
 Lower extremity 65% 64% 64% 3,773
Depth 
 Subcutaneous 34% 36% 37% 2,043
 Deep intramuscular 28% 28% 36% 1,715
 Deep extramuscular 32% 26% 23% 1,874
 Unclassifi ed 4% 2% 2% 205
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The surgical margin is assessed and determined by the sur-
geon and the pathologist in collaboration. 56% of patients had 
wide or better fi nal margins (Figure 1), but there has been a 
reduction in wide margins over the study period  (p < 0.001). 
Despite this change, there was less local failure after a mar-
ginal/wide margin in patients treated in the period 1997–2011 
than in those treated 1987–1996 (p < 0.001). The amputation 
rate fell from 5.9% in 1987–1996 to 3.5% in 2006–2011 (p < 
0.001).
At the same time, there has been an increase in the use 
of radiotherapy, particularly in patients with a wide margin 
(Table 7, Figure 2). There is increasing evidence that radio-
therapy improves local control regardless of the surgical mar-
gins (Trovik 2001, Jebsen et al. 2008). 3- and 5-year local 
recurrence rates (Kaplan-Meier estimates) were 20% and 
25%, respectively, in 1987–1996, 12% and 15% in 1996–
2006, and 14% (3-year) in 2006–2011. By univariate analy-
sis, local control was correlated  to the quality of the surgical 
margin (Figure 3).        
MFS was analyzed in 4,153 patients with no metastasis at 
diagnosis, who were surgically treated with curative intent 
at centers with adequate follow-up reporting. Comparing the 
period 1987–1996 with 1997–2006, 5-year estimated MFS 
increased from 67% to 73% (p < 0.005). There was no further 
statistically signifi cant increase when we compared the most 
recent period (2007–2011) with the previous one (Figure 2).
To investigate possible lasting differences in outcome 
between centers, we compared the rate of MFS among the 
Figure 1. Cumulative local recurrence rate 
according to margins in 4,143 patients 
treated with curative intent at centers with > 
4 years of follow-up of more than 75% of sur-
viving patients (p < 0.001). All margins tested 
against the others. Analysis was terminated 
at 100 cases left at risk. 
Table 7. Final margin distribution (%) and proportion of patients receiving radiation treatment according to 
margin status among 5,071 patients from the Scandinavian Sarcoma Group Central Register. The proportion 
of patients with a wide margin decreased (p < 0.001) and the proportion of patients having radiation treatment 
increased (p < 0.001)
 1987–1996 1997–2006 2007–2011 Total, n
  Radiation  Radiation  Radiation  Radiation
Margin Margin treatment Margin treatment Margin treatment Margin treatment
Intralesional 9% 41% 12% 33% 14% 37% 580 212
Marginal 35% 32% 40% 41% 39% 38% 1,925 716
Wide or better 56% 7% 48% 22% 47% 29% 2,566 433
Total, n 1,793 331 2,224 687 1,054 352 5,071 1,361
Cumulative local recurrence rate
Follow-up, years
0 4 8 12
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
Intralesional margin
Marginal margin
Wide margin
Figure 2 Metastasis-free survival in 4,153 
patients surgically treated in 3 time peri-
ods at centers with > 4 years of follow-up 
of more than 75% of surviving patients (p 
< 0.005). The period 1987–1996 was tested 
against the others. Analysis was terminated 
at 100 cases left at risk.
Probability of survival
Follow-up, years
0 4 8 12 16
1.0
0.9
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0.3
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0
1987–1996   
1997–2006 
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Cumulative survival
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0
Figure 3. Plot and results from Cox model of 
metastasis-free survival in 3,842 patients with 
soft-tissue sarcoma, according to 5 continu-
ously reporting hospitals in the Scandinavian 
Sarcoma Group Central Register. The Cox 
model included sex, age at diagnosis, tumor 
size, tumor depth, and malignancy grade. 
The plots are specifi ed for male sex, age = 59 
years, tumor size = 8.1 cm, deep tumor loca-
tion, and high grade of malignancy.
 Hazard ratio (95% CI)   p-value a 
 Hospital 0 1.00 Reference 0.01
 Hospital 1 0.95 (0.79–1.13) 
 Hospital 2 1.13 (0.92–1.40) 
 Hospital 3 0.70 (0.54–0.91) 
 Hospital 4 1.01 (0.85–1.21) 
 a Likelihood ratio test
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5 continuously reporting centers. There was no difference 
between these centers concerning treatment approach, and at 
all centers more than 95% of the patients who were referred 
were treated surgically for their primary tumors. Possible dif-
ferences in the distribution of prognostic factors in the patient 
materials were corrected for in a Cox multiple regression anal-
ysis. Hazard ratios for 4 centers were tested for signifi cance 
against the center with MFS results closest to the median 
(the reference center). 1 center differed signifi cantly from the 
others (Figure 3).  
Data for evaluation of overall survival and local recurrence-
free survival are not as reliable in the Register, as post-metas-
tasis treatment and events are not systematically recorded.
Discussion 
This is an overview of diagnosis and treatment results for 
the extremity and trunk wall soft-tissue sarcoma patients in 
4 Nordic countries over 25 years. The SSG Central Register 
can also be used to evaluate the Scandinavian model of orga-
nization of care. Of the centers that continuously report, some 
with a catchment population of 1–1.5 million inhabitants and 
some with more than 3.5 million are represented. The treat-
ment results are similar in the different participating centers. 
The MFS appeared to be better at the smallest center than at 
the reference center, but even though statistically signifi cant, 
the confi dence intervals almost overlapped and the clinical sig-
nifi cance is uncertain. Comparisons of results between centers 
must be interpreted with care. Even though these analyses are 
based on a close to population-based amount of cases, more 
than 25 years of observation may be needed for a regression 
to the mean for small centers. An apparent trend in survival 
analysis could also have been infl uenced by the longer follow-
up of all relapse-free survivors at the smaller centers, even if 
all the centers recorded all their relapse cases. There were also 
important demographic differences, differences in the distri-
bution of missing variables, and differences in the complete-
ness of registration of cause of death. 
3-year local recurrence rates for the entire period (12–18%) 
were similar between centers.
It has been reported that treatment guidelines are followed 
more closely at larger centers (Nijhuis et al. 2001), and that 
results are better (Gutierrez et al. 2007), but the defi nition of 
a large center in these studies has been generous (> 10 new 
patients per year), and these were compared with very small 
centers (< 1 case per year on average). All the Scandinavian 
centers are large enough to be able to run a multidisciplinary 
sarcoma team (MDT) (with more than 25 new sarcoma cases a 
year), and there appear to be similar results at all centers. When 
there is cooperation among the centers, the Scandinavian model 
of 10–12 centers each with a catchment population of 1–4 
million inhabitants may represent a well-functioning balance 
between centralized expertise and practical referral distances.
Even though the use of chemotherapy has increased over the 
years (Jebsen et al. 2011), the slightly better survival is most 
likely due to better centralization to sarcoma centers where 
treatment decisions are made by the MDT (El Saghir et al. 
2014). Scandinavian sarcoma care was among the fi rst tumor 
services to emphasize centralization to MDT boards and to 
use them as vital instruments for decision making. The main 
surgical achievements that have resulted from centralization 
of care to sarcoma centers are less amputations, fewer opera-
tions, and better local control.
Median tumor size at diagnosis was constant, although a 
reduction in size may be masked by more reliance on MRI 
measurements preoperatively in recent years, compared to 
pathologist measurements in the early years. In later years, 
more tumors have been classifi ed as intramuscular, but this too 
may have been due to better classifi cation by MRI rather than 
to less extensive growth at diagnosis.
Surprisingly, the proportion of patients with metastasis at 
diagnosis was unchanged during the study period. This may 
refl ect that metastasis is more related to tumor biology than to 
tumor size, or it may refl ect early detection due to routine use 
of chest CT. CT is still not mandatory at initial staging of sar-
coma patients in Scandinavia, but is being increasingly used.
The mainstay of soft-tissue sarcoma treatment is surgical 
excision. Important differences concerning the use of adjuvant 
therapy still exist today. The Scandinavian countries have tra-
ditionally used less adjuvant therapy, especially less adjuvant 
radiotherapy than North American centers (and lower doses of 
radiotherapy).
There appears to be a changing attitude among Scandinavian 
surgeons concerning the importance of a wide margin, paral-
lel to the increase in the use of radiotherapy. Wide margins 
are achieved less often than they were 20 years ago, despite a 
reduction in numbers of patients who are referred after opera-
tions or open biopsies. The classifi cation of margins is coher-
ent across centers (Trovik et al. 2012). The local recurrence 
rates being related to the various types of margins highlights 
the relevance of this classifi cation, and the reliability of the 
margin assessments in a Scandinavian setting (Figure 2).
MRI provides precise measurements and better anatomi-
cal resolution, leading to the use of closer margins—i.e. more 
marginal margins than wide margins. Local control after a 
marginal/wide margin has, however, improved over the years, 
indicating that this change of attitude in combination with 
increased use of radiotherapy can be justifi ed. 
As more extensive use of radiotherapy has been introduced 
in Scandinavia, the associated increased risk of radiation-
induced sarcoma should be monitored closely by the Register 
(Bjerkehagen et al. 2013).
Since the creation of the SSG Central Register, numerous 
other registry-based publications have described demographic 
parameters for sarcoma patients and prognostic factors for 
outcome—sometimes based on more than 25,000 patients 
(Jacobs et al. 2015, Ng et al. 2013). The original ambition of 
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the SSG, to contribute to the general knowledge of the disease, 
can therefore be regarded as having been accomplished. It will 
now be more interesting to test Register-generated hypotheses 
using specifi c treatment protocols. Furthermore, the Regis-
ter’s main function may be to provide data on well-defi ned 
subgroups for genomic and proteomic analyses. Most centers 
preserve tumor tissue in bio-banks. 
When the SSG Central Register published the 10-year results 
15 years ago, better compliance of registration was anticipated 
(Bauer et al. 2001). Annual accrual has increased, but the com-
pleteness of registration has declined somewhat. 25 years ago, 
standards of quality were defi ned by professionals involved 
in the treatment of sarcoma patients, and the main focus was 
on treatment results related to referral practice and centralized 
surgical treatment. In recent years, service-related parameters 
seem to be more important. Government and administrative 
bodies are increasingly taking an interest in monitoring deci-
sion making and time to diagnostic and treatment procedures, 
both inside and outside sarcoma centers. But the focus is on 
time to decision rather than quality of decision. The ambition 
to do meaningful monitoring of such parameters is crucially 
dependent on complete reporting. If only those centers that 
have an adequate organization report to the register, nothing 
will be known about those that really need to be monitored. 
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